MedTrace Logo

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis

NCT01809769 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-04-04

No results posted yet for this study

Summary

Two injections in total and 3 ml autologous adipose-tissue-derived stem cells(haMSCs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injection.

Conditions

Interventions

BIOLOGICAL

Mesenchymal stem cells low-dose group

Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use

BIOLOGICAL

Mesenchymal stem cells mid-dose group

Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use

BIOLOGICAL

Mesenchymal stem cells high-dose group

Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use

Sponsors & Collaborators

  • RenJi Hospital

    collaborator OTHER

  • Shanghai AbelZeta Ltd.

    lead INDUSTRY

Principal Investigators

  • Chunde Bao, M.D. & Ph.D. · Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-03-31
Completion
2015-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01809769 on ClinicalTrials.gov